Heart health
ACC statement outlines strategies for earlier lipid-lowering treatment
The ACC statement recommends tailoring lipid-lowering decisions using short- and long-term risk, lipid burden, risk enhancers, imaging when appropriate and patient preferences.

Published in JACC, the 2026 statement reviews evidence and offers consensus recommendations on risk enhancers, imaging to assess risk, combination therapy and areas for future research.
The writing committee said there is a strong rationale for earlier and longer-term lipid lowering, including lifestyle management and medications, for people with elevated ASCVD risk, particularly when they have had earlier exposure to unfavorable lipid levels. It recommends that clinicians consider short- and long-term risk, lipid burden, risk enhancers, imaging findings when appropriate, and patient preferences when making individualized decisions. The committee said further research should assess the effectiveness, safety, adherence and cost-effectiveness of treatment for people without clinical ASCVD, including asymptomatic young adults who may benefit but do not have a current indication.


